XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company�s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company�s preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo, named XMet, and represent potential new therapeutic approaches to the treatment of diabetes and several diseases that have insulin involvement. On January 17, 2012, it announced that it had acquired certain the United States rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON (perindopril erbumine), a marketed angiotensin converting enzyme (ACE) inhibitor, and three fixed-dose combination (FDC) product candidates where a form of perindopril (perindopril arginine) is combined with another active ingredient.